REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN

被引：2
|
作者：
Amin, Alpesh
Keshishian, Allison
Xie, Lin
Baser, Onur
Price, Kwanza
Vo, Lien
Mardekian, Jack
Mendoza, Mario
Singhal, Shalabh
Patel, Chad
Odell, Kevin
Trocio, Jeffrey
机构：
[1] Pfizer Inc, New York, NY USA
[2] Bristol Myers Squibb Co, New York, NY 10154 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2016年 / 67卷 / 13期
关键词：
D O I：
10.1016/S0735-1097(16)30669-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1130M-13
引用
收藏
页码：668 / 668
页数：1
相关论文
共 50 条
  • [1] Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin
    Lip, G. Y. H.
    Pan, X.
    Kamble, S.
    Kawabata, H.
    Mardekian, J.
    Masseria, C.
    Bruno, A.
    Phatak, H.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1085 - 1085
  • [2] BLEEDING RISK AMONG JAPANESE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATED ON APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN IN THE REAL WORLD
    Wang, Feng
    Murata, Tatsunori
    Izumi, Naoko
    Kida, Makoto
    Horblyuk, Ruslan
    Terayama, Yasuo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 443 - 443
  • [3] Major bleeding risk in elderly patients age ≥ 75 years with non-valvular atrial fibrillation initiating oral anticoagulants: A 'real-world' comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Burns, Leah
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    Squibb, Bristol-Myers
    [J]. PHARMACOTHERAPY, 2016, 36 (12): : E213 - E213
  • [4] Major bleeding risk in patients 75 years of age or older with non-valvular atrial fibrillation initiating oral anticoagulants: a real-world comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Lip, G. Y. H.
    Keshishian, A.
    Kamble, S.
    Pan, X.
    Burns, L.
    Mardekian, J.
    Horbkyuk, R.
    Hamilton, M.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 500 - 501
  • [5] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Tepper, Ping G.
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    Kamble, Shital
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    [J]. PLOS ONE, 2018, 13 (11):
  • [6] Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin A propensity score matched analysis
    Lip, Gregory Y. H.
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    [J]. THROMBOSIS AND HAEMOSTASIS, 2016, 116 (05) : 975 - 986
  • [7] Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States
    Lip, Gregory Y. H.
    Pan, Xianying
    Kamble, Shital
    Kawabata, Hugh
    Mardekian, Jack
    Masseria, Cristina
    Bruno, Amanda
    Phatak, Hemant
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (09) : 752 - 763
  • [8] REAL-WORLD COMPARISON OF MAJOR BLEEDING AND ASSOCIATED COSTS AMONG ORAL ANTICOAGULANT-NAIVE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN IN THE US MEDICARE POPULATION
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Le, Hannah
    Dina, Oluwaseyi
    Qisu, Zhang
    Baser, Onur
    Vo, Lien
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 439 - 439
  • [9] Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records
    Lin, I.
    Masseria, C.
    Mardekian, J.
    Frean, M.
    Phatak, H.
    Kamble, S.
    Abdulsattar, Y.
    Petkun, W.
    Menzin, J.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084
  • [10] Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population
    Amin, A.
    Keshishian, A.
    Trocio, J.
    Dina, O.
    Le, H.
    Rosenblatt, L.
    Mardekian, J.
    Zhang, Q.
    Baser, O.
    Liu, X.
    Vo, L.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 964 - 964
12345